Tinea Pedis Clinical Trial
Official title:
An Observer-Blinded, Randomized, Aqueous Gel Controlled Trial of the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Interdigital Tinea Pedis
Verified date | September 2022 |
Source | DermBiont, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, observer blinded, Aqueous Gel-controlled trial examining the effect of daily application for approximately 6-8 days of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel on the subjects with interdigital tinea pedis based on Whole Genome Sequencing (WGS) and Quantitative Polymerase Chain Reaction (qPCR), and comparison between Quantitative Polymerase Chain Reaction (qPCR) and Potassium Hydroxide (KOH) for the presence of Trichophyton rubrum (T.rubrum) as well as signs and symptoms and local tolerability and toxicity on treated sites in subjects.
Status | Active, not recruiting |
Enrollment | 24 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Ability to understand, agree to, and sign the study Informed Consent 2. A signed Health Information Portability and Accountability Act (HIPAA) authorization form which permits the use and disclosure of the subject's individually identifiable health information. 3. Male or Female Subjects of any race 18-65 years of age. 4. Subjects with a clinical diagnosis of interdigital T. pedis. 5. Investigator confirmed diagnosis by a positive T. rubrum potassium hydroxide (KOH) wet mount at Screening at the investigative site. 6. A quantifiable level of T. rubrum based on Sponsor laboratory qPCR from the sample obtained at the Screening visit. 7. The sum of the clinical signs and symptoms scores of at least one web space (Target web space) is at least 4 using the Grading of Signs and Symptoms of T. pedis including a minimum score of 2 for erythema AND a minimum score of 2 for either scaling/fissures or pruritus/burning (on a scale of 0-3, where 2 indicates moderate severity). 8. Target web space(s) should have an adequate amount of leading-edge scale to provide enough scale sampling for KOH. Exclusion Criteria: 1. Women who are pregnant, planning a pregnancy, breastfeeding or have a positive pregnancy test at screening. 2. Any dermatological conditions that could interfere with clinical evaluations 3. The clinical diagnosis of moccasin T. pedis. 4. Subjects with gram negative interdigital tinea pedis based on a clinical diagnosis: Gram-negative athlete's foot - the interspace is foul smelling, whitish, painful, strongly macerated, and hyperkeratotic with erosions, exudation, and intense inflammation and often disabling. 5. Any underlying disease(s) or other dermatological condition that requires the use of interfering topical or systemic therapy. 6. Subjects with concurrent use of any of the following topical preparations who have not completed the specified washout period(s) for the following topical medications applied to the foot at the time of the Screening visit: 1. Washout of 1 week prior to the screening visit for topical astringents and abrasives (e.g., Burrow's solution), Vicks VapoRub, tea tree oil) 2. Washout of 2 weeks prior to the screening visit for topical antibiotics and antifungal on the feet (e.g., Neomycin, Miconazole, Clotrimazole, Terbinafine) 3. Washout of 4 weeks prior to the screening visit for the topical Anti-inflammatories, corticosteroids, topical immunomodulators on the feet (e.g., Pimecrolimus, Tacrolimus) 7. Subjects with concurrent use of any of the following systemic medications who have not completed the specified washout period(s) for the following systemic medications at the time of the Screening visit: 1. Washout of 4 weeks prior to the screening visit for the systemic corticosteroids (including intramuscular injections) (e.g., Triamcinolone acetonide) 2. Washout of 4 weeks prior to the screening visit for the systemic antibiotics (e.g., Tetracycline, Cephalosporins, etc.) and/or Antifungal agents (e.g., Fluconazole, Itraconazole, Terbinafine, etc.) 3. Washout of 4 weeks prior to the screening visit for the systemic immunomodulators (e.g., Cyclophosphamide, Azathioprine, Biologicals-Monoclonal Antibodies) 8. Treatment of any type of cancer within the last 6 months except for superficial skin cancers such as basal cell carcinoma and squamous cell carcinoma. 9. History of any significant internal disease which contraindicates use of a live microbiome (e.g., leukemia, liver failure, cardiovascular disease). 10. Subjects who are known to be allergic to any of the Test article(s) or any components in the test article(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure. 11. AIDS or AIDS related complex by medical history. 12. History of current street drug or alcohol abuse, or street drug or alcohol abuse within the past year. 13. Known or suspected immune suppressive medications or diseases. 14. Subjects with poorly controlled diabetes mellitus Type I or II requiring medical intervention/treatment. 15. Peripheral vascular disease based on medical history. 16. Any subject not able to meet the study attendance requirements. 17. Subjects who have participated in any other trial of an investigational drug or device within 30 days prior to enrollment or participation in a research study concurrent with this study. 18. Use of any orthopedic appliance (e.g., cast, soft cast, splint) on either foot or ankle, or surgery of either foot or ankle within 90 days of the Screening visit. |
Country | Name | City | State |
---|---|---|---|
United States | Oregon Dermatology and Research | Portland | Oregon |
United States | Premier Clinical Research | Spokane | Washington |
Lead Sponsor | Collaborator |
---|---|
DermBiont, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in abundance of T. rubrum based on Quantitative Polymerase Chain Reaction (qPCR) | Change in abundance of T. rubrum at baseline, day 7 and day 14 | 14 days of participation | |
Secondary | Number of participants with treatment-related adverse events | Safety | 14 days of participation | |
Secondary | Changes in signs and symptoms of T. Pedis | Change from baseline in individual signs and symptoms of Tinea Pedis at days 7 and 14 of sites treated with DBI-001 Gel, DBI-002 Gel, or Aqueous Gel. The minimum value is 0 and the maximum value is 3 the subject's self reported observation on local tolerability. | 14 days of participation | |
Secondary | Changes in the signs and symptoms and Investigators Static Global Assessment (ISGA) of Tinea Pedis | Changes from Baseline in signs and symptoms and ISGA at Days 7 and 14 | 14 days of participation | |
Secondary | Change in abundance of T. rubrum based on qPCR and WGS | Antimicrobial efficacy | 14 days of participation | |
Secondary | Molecular diagnostic qPCR and WGS comparison of DBI-001 Gel, DBI-002 Gel and Aqueous Gel | Antimicrobial efficacy and microbiome community analysis | 14 days of participation | |
Secondary | Bacterial culture comparison of DBI-001 Gel, DBI-002 Gel and Aqueous Gel | Antimicrobial efficacy and microbiome community analysis | 14 days of participation | |
Secondary | Increase or decrease of colony forming units after DBI-001 Gel, DBI-002 Gel application | Antimicrobial efficacy | 14 days of participation | |
Secondary | Correlation between levels of DBI-001 Gel, DBI-002 Gel and abundance of T. rubrum based on qPCR | Antimicrobial efficacy | 14 days of participation | |
Secondary | Correlation between qPCR quantification and KOH for presence of T. rubrum at screening | Compare sensitivity and specificity of qPCR analysis and KOH for presence of T. rubrum at Screening | 28 days from screening |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04883593 -
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
|
Early Phase 1 | |
Terminated |
NCT02842021 -
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
|
Phase 2 | |
Completed |
NCT01712360 -
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
|
Phase 4 | |
Completed |
NCT00781664 -
Cumulative Irritation Test
|
Phase 1 | |
Completed |
NCT03676686 -
Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis
|
N/A | |
Completed |
NCT01519752 -
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
|
Phase 1 | |
Completed |
NCT03320486 -
Non-inferiority Trial of Dapaconazole Versus Ketoconazole
|
Phase 3 | |
Completed |
NCT01580891 -
Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
|
Phase 1 | |
Completed |
NCT01353976 -
Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
|
Phase 3 | |
Completed |
NCT01349998 -
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
|
Phase 3 | |
Completed |
NCT04265521 -
Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet
|
N/A | |
Completed |
NCT02633813 -
BE Study of Naftifine HCL
|
Phase 3 | |
Recruiting |
NCT00856596 -
Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females
|
Phase 3 | |
Completed |
NCT00869336 -
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
|
Phase 2 | |
Completed |
NCT00768599 -
A Study of Econazole Foam 1% in Athlete's Foot
|
Phase 2 | |
Recruiting |
NCT00233493 -
Spread of Dermatophytes Among Families
|
N/A | |
Completed |
NCT03897257 -
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
|
Phase 2 | |
Completed |
NCT03129321 -
Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
|
Phase 3 | |
Completed |
NCT02335255 -
Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis
|
Phase 1 | |
Withdrawn |
NCT02606383 -
Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis
|
Phase 3 |